Back to top
more

Patterson Companies (PDCO)

(Delayed Data from NSDQ)

$21.05 USD

21.05
955,878

+0.25 (1.20%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $21.05 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) broad product line.

Thermo Fisher (TMO) Completes the CorEvitas Acquisition

by Zacks Equity Research

Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.

West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Patterson Cos. (PDCO) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Patterson Cos. (PDCO) closed at $33.83 in the latest trading session, marking a -1.4% move from the prior day.

PDCO or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Cardinal Health (CAH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 4.73% and 2%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.

Reasons to Add Patterson Companies (PDCO) to Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Rockwell Medical (RMTI) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Robust product demand and cost-saving initiatives are likely to have boosted Rockwell Medical's (RMTI) second quarter's top line.

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Indrajit Bandyopadhyay headshot

3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates

by Indrajit Bandyopadhyay

Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.

ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 2.70% and 5.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Patterson Cos. (PDCO) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Patterson Cos. (PDCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.

Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study

by Zacks Equity Research

Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.

Patterson Cos. (PDCO) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Patterson Cos. (PDCO) closed at $33.37, marking a +0.45% move from the previous day.

SmileDirectClub (SDC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

SmileDirectClub (SDC) delivered earnings and revenue surprises of -8.33% and 1.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

Charles River (CRL) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.

Patterson Cos. (PDCO) Up 3.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Patterson Cos. (PDCO) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Patterson Cos. (PDCO) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Patterson Cos. (PDCO) closed at $32.53 in the latest trading session, marking a +1.43% move from the prior day.